Uploaded May 2026 | Updated November 2026, 4 days ago
New research published in The Lancet (May 2026) finally answers one of the
biggest questions in obesity medicine: what happens when you stop or lower
your dose of tirzepatide (Zepbound/Mounjaro) after losing weight?
In this episode of The Weekly Shot, we break down the SURMOUNT-MAINTAIN
trial — the first randomized controlled trial to study dose reduction as a
maintenance strategy after weight loss on a GLP-1 medication.
Here's what we cover:
✅ How SURMOUNT-MAINTAIN builds on the SURMOUNT-4 trial
✅ What happened to weight AND cardiometabolic health when patients stopped
✅ Why lifestyle changes alone weren't enough to maintain weight loss
✅ The difference between full doses (5mg, 10mg, 15mg) and transitional doses
✅ What the data means for patients worried about staying on medication long term
✅ The real talk on insurance coverage and dose decisions
The results challenge one of the most common beliefs patients hear from
providers and online: that if you just build the right habits while on the
medication, you can eventually come off it and maintain your results. Two out
of three patients who stopped the medication regained significant weight —
even while continuing diet and exercise counseling.
This is not a willpower story. This is a biology story.
⚠️ This video is for educational purposes only and is not medical advice.
Always consult your healthcare provider before making any changes to your
medication.
🔔 Subscribe for weekly breakdowns of the latest in obesity medicine, GLP-1
research, and metabolic health.
——————————————————————————
📚 STUDY REFERENCED:
Horn et al. "Tirzepatide for maintenance of bodyweight reduction in people
with obesity in the USA (SURMOUNT-MAINTAIN)" The Lancet, May 12, 2026.
DOI: 10.1016/S0140-6736(26)00656-2
thelancet.com/journals/lancet/article/PIIS0140-6736(26)00656-2/fulltext
=======================================================
Affiliate Links (I earn commission for qualifying purchases)
Join Fridays (GLP-1/TRT) Use Code RMZ: joinfridays.com/?via=RMZ
Gruns: grns.sjv.io/AgoLV7
========================================================
Social Links
tiktok.com/@roundmoundofzepbound
instagram.com/roundmoundofzepbound
========================================================
DISCLAIMER: No information provided here is to be construed as medical advice. Always consult with a licensed medical provider for medical advice.
#glp1 #zepbound #mounjaro #weightloss #weightlossjourney #glp #tirzepatide #semaglutide #wegovy #ozempic #menshealth #beforeandafter #beforeandafterweightloss
New research published in The Lancet (May 2026) finally answers one of the
biggest questions in obesity medicine: what happens when you stop or lower
your dose of tirzepatide (Zepbound/Mounjaro) after losing weight?
In this episode of The Weekly Shot, we break down the SURMOUNT-MAINTAIN
trial — the first randomized controlled trial to study dose reduction as a
maintenance strategy after weight loss on a GLP-1 medication.
Here's what we cover:
✅ How SURMOUNT-MAINTAIN builds on the SURMOUNT-4 trial
✅ What happened to weight AND cardiometabolic health when patients stopped
✅ Why lifestyle changes alone weren't enough to maintain weight loss
✅ The difference between full doses (5mg, 10mg, 15mg) and transitional doses
✅ What the data means for patients worried about staying on medication long term
✅ The real talk on insurance coverage and dose decisions
The results challenge one of the most common beliefs patients hear from
providers and online: that if you just build the right habits while on the
medication, you can eventually come off it and maintain your results. Two out
of three patients who stopped the medication regained significant weight —
even while continuing diet and exercise counseling.
This is not a willpower story. This is a biology story.
⚠️ This video is for educational purposes only and is not medical advice.
Always consult your healthcare provider before making any changes to your
medication.
🔔 Subscribe for weekly breakdowns of the latest in obesity medicine, GLP-1
research, and metabolic health.
——————————————————————————
📚 STUDY REFERENCED:
Horn et al. "Tirzepatide for maintenance of bodyweight reduction in people
with obesity in the USA (SURMOUNT-MAINTAIN)" The Lancet, May 12, 2026.
DOI: 10.1016/S0140-6736(26)00656-2
thelancet.com/journals/lancet/article/PIIS0140-6736(26)00656-2/fulltext
=======================================================
Affiliate Links (I earn commission for qualifying purchases)
Join Fridays (GLP-1/TRT) Use Code RMZ: joinfridays.com/?via=RMZ
Gruns: grns.sjv.io/AgoLV7
========================================================
Social Links
tiktok.com/@roundmoundofzepbound
instagram.com/roundmoundofzepbound
========================================================
DISCLAIMER: No information provided here is to be construed as medical advice. Always consult with a licensed medical provider for medical advice.
#glp1 #zepbound #mounjaro #weightloss #weightlossjourney #glp #tirzepatide #semaglutide #wegovy #ozempic #menshealth #beforeandafter #beforeandafterweightloss










